Aptahem is now able to announce that the development of a completely new bioanalysis method has been finalized in collaboration with our partner Axolab in Germany. The new method has a better resolution and can detect lower levels of...
Read More”Aptahem’s drug candidate shows sensationally good results in sepsis studies” The scientific advisory board has now been in place for almost a year, and we have interviewed the president of the board, Dr. Anders Bylock, about what has happened...
Read MoreAptahem (publ) announced today that the company has submitted a new patent application based on the latest research results of Apta-1, with the aim of strengthening the company’s intellectual property rights portfolio. The new patent application is based on...
Read MoreAptahem (publ) can announce today new positive results from an extended study performed with Hooke Laboratories (US), the collaborating partner. The results show that intravenous administration of Apta-1 correlates with an improved survival rate in test animals. The outcome...
Read MoreAptahem AB (publ) can announce today that the company’s board has finalized a revised development plan for the drug candidate Apta-1. The new development plan was established together with the company’s scientific advisory board who assessed Apta-1’s pharmacological properties....
Read MoreAptahem AB (publ) can announce today that it has entered into a production agreement with BioSpring, a world-leading producer of oligonucleotides. BioSpring has been contracted to manufacture the substance in drug candidate Apta-1 for the company’s preclinical and upcoming...
Read MoreAptahem (publ) can today announce a positive outcome from a study performed in collaboration with Hooke Laboratories (US). The study evaluated the pharmaceutical candidate Apta-1 in a clinically relevant model for sepsis which showed a significant improvement in survival...
Read MoreAptahem’s preclinical programme is proceeding with the gradual collection of data on the Apta-1 effect profile, while the work on the company’s clinical development is proceeding in consultation with external experts. Dialogue with opinion leaders and potential partners has...
Read MoreAptahem can today announce that it has entered into an agreement with lecturer and registered practitioner Anders Bylock, a well-known expert on issues related to cardiovascular treatment including pre-clinical development, clinical trials and regulatory submissions. Dr Bylock will provide...
Read MoreQuintilesIMS publish updates from Aptahem in their newsletter Drug News in December 2016 (see page 15). Aptahem’s CEO Mikael Lindstam presented the information at Bio Europe in Cologne in November 2016. Open Drug News For further information: Mikael Lindstam,...
Read More